---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-23-000049"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:46:09.442592+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen Q2 2023: Revenue up 6% to $7.0B; Non-GAAP EPS rises 8% to $5.00

## Summary
- Total revenues increased 6% to $7.0B; product sales volume growth of 11% partially offset by FX and price.
- GAAP EPS $2.57 (up 5% YoY); Non-GAAP EPS $5.00 (up 8% YoY), driven by record revenues.
- Free cash flow $3.8B vs $1.7B in Q2 2022, due to timing of tax payments and higher income.
- Pipeline: positive top-line for tarlatamab in small cell lung cancer and LUMAKRAS+Vectibix in colorectal cancer.
- Volume growth double-digit for EVENITY, BLINCYTO, Repatha, LUMAKRAS, Vectibix, KYPROLIS, Nplate, AMJEVITA.

## SEC filing metadata
- accession: 0000318154-23-000049
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/0000318154-23-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/amgn-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-23-000049
- JSON: https://secwatch.observer/filing/0000318154-23-000049.json
- Plain text: https://secwatch.observer/filing/0000318154-23-000049.txt

## Key facts
- Earnings Releases
  AMGEN INC reported the second quarter of 2023 results: revenue $7.0 billion, EPS $5.00.
  - Period: the second quarter of 2023
  - Revenue: $7.0 billion
  - EPS: $5.00
  - Result: reported results
  source text: shared today illustrates the rapid progress we are making in advancing our pipeline of potential first-in-class medicines." Key results include: • Total revenues increased 6% to $7.0 billion in comparison to the second quarter of 2022, resulting from a 6% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 2% lower
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/0000318154-23-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.